Lv11
100 积分 2023-10-16 加入
Integrating Multiple Outcomes of First-Line Immunotherapy-Based Regimens for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials
4小时前
待确认
Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab
1个月前
已关闭
Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
1个月前
已完结
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
1个月前
已完结
Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
1个月前
已完结
CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis
1个月前
已关闭
Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
4个月前
已关闭
皖公网安备34019202002308
